株式会社ライフバンクジャパン 本文へジャンプ




UNDER CONSTRUCTION

Company Profile
Name
Representative
Address

Establishment
Capital
Number of
 employees
Category
Business
 descrition













Tel. Fax
LifeBankJapan, Inc.
Tsuneo A Takahashi, D, Sc
4-7, International Medical Device Alliance, 1-6-5, Minatojima Minamimachi, Chuo-ku, Kobe City, Hyogo, 650-0047 Japan
June 13, 2015
75,100,000 JPY
Executive 2, Employe 2, Temp 1

Cell processing / supply business
1. The company is led by a consortium of academic scientists
 with the goal to use the human mesenchymal stem cells
 (hMSC) and their data (see 2-4 below) to develop predictors
 of disease that may be used for health promotion.
2. Measure factors in umbilical cord blood serum
 (environmental chemicals, etc.) that might be associated
 with or cause health problems in the future and inform and
 counsel the parents about potential risks.
3. Collect, isolate, process and cryopreserve high quality
 hMSCs (mainly derived from placental and umbilical cord
 connective tissue) for research purposes.
4. Assess the hMSC’ biological properties (genomic and
 epigenomic) and maintain accurate documentation of this
 data and its retention under strict confidentiality
 precautions.Secure financial support of the research.
TEL +81(0)78-335-8246
FAX +81(0)78-335-8247
info@lifebankjapan.jp

Purpose of business, business model
Purpose of
 business



Expected
 outcome
 and future
 business
 model
Development of technologies and devices for the collection,
culture and preservation of human mesenchymal stem cells
(hMSC). Promotion support for new health and medical industry
that possesses high public interest, high productivity and
sustainable growth.
1. Development of devices for hMSC isolation, identification
 andanalytic methods to characterize these cells and contribute
 totheir international standardization.
2. Promotion of the analysis of the mutual relationship of various
 useful data that MSC.
3. Shared use of the hMSC and the information of the cells from
 the universities and research institute 4. Acceleration of global
 research and development on technologies for personalized
 medicine, ICT health care, prevention and early diagnosis and
 treatment and related equipment.